Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients.

ABSTRACT:

Background

Most non-small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK-TKI therapies; however, little clinical data exists on the clinical efficacy of ALK-TKI tailored to secondary mutation.

Methods

A retrospective study was conducted to analyze the patterns of ALK-TKI treatment and clinical outcomes, including progression free survival (PFS), of ALK-positive NSCLC patients who received rebiopsy. Based on the rebiopsy results, secondary mutations in the ALK gene that were shown to be associated with the efficacy of ALK-TKI therapy in the preclinical or clinical setting were defined as "sensitive m

SUBMITTER: Haratake N 

PROVIDER: S-EPMC6718030 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature